Association Between Microplastic Exposure and the Pathological Progression of Gastric Carcinogenesis

The objective of this clinical trial is to explore the correlation between the level of microplastic exposure and the risk of gastric mucosal carcinogenesis, and to evaluate the strength of its effect as an independent risk factor. The main questions it aims to answer include: Does the level of microplastic exposure increase the risk of gastric mucosal carcinogenesis? Can the correlation between the level of microplastic exposure and gastric mucosal carcinogenesis, as well as the sources of high - risk microplastic exposure, be explored through a questionnaire on external microplastic exposure? Researchers will complete a design structured questionnaire and ask participants to fill it out carefully and truthfully to determine whether the level of microplastic exposure increases the risk of gastric mucosal carcinogenesis.

The study will categorize participants into three groups based on endoscopic and/or histopathological findings: chronic non-atrophic gastritis, precancerous lesions, and gastric cancer. Basic demographic information, \*Helicobacter pylori\* infection status, and plastic exposure assessment scores will be recorded for each group.

Inclusion Criteria: (1) Aged between 18 and 75 years old, gender is not restricted; (2) Having a clear diagnosis result within the recent three months and being diagnosed with chronic non - atrophic gastritis, precancerous lesions of gastric cancer, or gastric cancer for the first time; (3) Have clear Helicobacter pylori (Hp) test results (including 13C/14C urea breath test, rapid urease test, and fecal Hp antigen test); (4) Be in normal mental state and able to independently complete the questionnaire survey. \- Exclusion Criteria: 1. Patients with a history of malignant tumors in other parts; 2. Patients who have previously undergone upper gastrointestinal surgery, chemotherapy, or radiotherapy; 3. Patients with severe diseases of major organs such as the heart, lungs liver, and kidneys; 4. Patients who are currently receiving psychological intervention or taking psychiatric drugs; 5. Pregnant or lactating women; 6. Patients with severe missing clinical data or questionnaire information; 7. Refusing to sign the informed consent form -